Treehouse Eyes Start Date Month/Year
In April 2021, the World Council of Optometry passed a resolution that declares support for myopia management as standard of care1
1. World Council of Optometry. Resolution: The standard of care for Myopia Management by Optometrists. https://worldcouncilofoptometry.info/resolution-the-standard-of-care-for-myopia-management-by-optometrists. Accessed 2nd March 2022.
Evidence-based standard of care combines three main components:
MITIGATION
MEASUREMENT
MANAGEMENT
COVID Myopia looking at 123,535 children 1.4x to 3x WORSE
Progression of Myopia in School-Aged Children After COVID-19 Home Confinement
Jiaxing Wang, MD, PhD1; Ying Li, MD, PhD1; David C. Musch, PhD, MPH2; et al
Nan Wei, MD3; Xiaoli Qi, MD3; Gang Ding, MD3; Xue Li, MD3; Jing Li, MD3; Linlin Song, MD3; Ying Zhang, MD3; Yuxian Ning, MD3; Xiaoyu Zeng, MD3; Ning Hua, MD3; Shuo Li, MD, PhD4; Xuehan Qian, MD, PhD3
Author Affiliations Article Information
JAMA Ophthalmol. 2021;139(3):293-300. doi:10.1001/jamaophthalmol.2020.6239
| 2015-2019 average | 2020 after quarantine |
6 Year Olds | 5.7% | 21.5% |
7 Year Olds | 16.2% | 26.2% |
8 Year Olds | 27.7% | 37.7% |
For every 1 Diopter of myopia progression reduced, we can reduce the risk of myopic maculopathy by 40%
Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci. 2019 Jun;96(6):463-465. doi: 10.1097/OPX.0000000000001367. PMID: 31116165.
Eyes are Supposed to Grow
Emmetropes: 0.20 mm slowing to 0.10 mm per year
Refractive error projection of an emmetropic 5 year old (purple) vs real patient data treated with atropine
Example of a child who refused Tx for 2 years and progressed. Triangles represent AXL stability with treatment
Myopia Risk Factors
Myopia Suspects (like GLC!)–Prediction of Juvenile Onset CLEERE study
6 year olds | 7-8 Year Olds | 9-10 Year olds | 11 Year |
+0.75 | +0.50 | +0.25 | 0.00 |
What's causing all this myopia?
The classic Nature Argument
FedOpto Medillian Columbia 2015
Dr. Monica Jong, Brien Holden Vision Institute
“70% of today’s myopia is environmentally driven. 30% is genetic.”
[
[
]
Outdoor Activities
The more the better!
~2% reduction in risk/hr/wk
What about Diet?
Conclusion: Higher saturated fats and cholesterol intake are associated with longer axial length in otherwise healthy children
When parents ask about �screentime . . .
Questions
Spectacle Treatments
Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
Diffusion Optics (CYPRESS)
Looked into how reducing contrast in glasses can reduce myopia progression
Undercorrection doesn’t work
The importance of adherence to recommended wear time:
Bao J, Huang Y, Li X, et al. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022;140(5):472–478.
Stellest™ lens Control (Single vision)
Highly Aspheric Lenslets group
Graph comparing axial elongation between test and control groups during 2-year treatment period1
59% slowing
39% slowing
FULL-TIME WEARING GROUP
(≥12 hours/day)
50% faster progression
for part-time wearers
PART-TIME WEARING GROUP
(<12 hours/day)
n=32
n=22
n=16
n=34
Questions
Soft Multifocal Treatments
26
Eef van der Worp, Giancarlo Montani. Powerful Profiles. Contact Lens Spectrum, April 2023.
Cumulative MiSight Effect over 10 years provides an estimated 0.87mm of Slowing Eye Growth = more than 2.00D of Myopia Control
**Analysis of treatment age and years in treatment needs further investigation and likely that both can be utilized to demonstrate treatment efficacy.
Analysis of MiSight study result by subject age
Average cumulative treatment effect
Approximately 50% slowing at each age.
1% Atropine worked!
ATOM 1
ATOM 2
0.5% vs 0.1% vs 0.01%
Efficacy Results from the Atropine in the Treatment of Myopia (ATOM) StudyW. Chua; V. Balakrishnan; D. Tan; Y. Chan; ATOM Study Group Invest Ophthal Published:2006 ,
5 Year Clinical Trial Atropine in the Treatment of Myopia (ATOM2) StudyW. Chua; V. Balakrishnan; D. Tan; Y. Chan; ATOM Study Group Invest Ophthal Published:2014 ,
LAMP
438 Children ages 4-12 with myopia at least 1.0 Diopter over a year
4 groups:
0.05%, 0.025%, 0.01% and placebo given nightly to both eyes for 1 year
Randomized, double masked
Results (p < 0.001) Refractive error
0.05% | -0.27 +/- 0.61D |
0.025% | -0.46 +/- 0.45D |
0.01% | -0.59 +/- 0.61D |
Placebo | -0.81 +/- 0.53D |
Results (p < 0.001) Axial Length
0.05% | 0.20 +/- 0.25mm |
0.025% | 0.29 +/- 0.20mm |
0.01% | 0.36 +/- 0.29mm |
Placebo | 0.41+/- 0.22mm |
Results (p < 0.001) Accommodation
0.05% | 1.98 +/- 2.82 D |
0.025% | 1.61 +/- 2.61 D |
0.01% | 0.26 +/- 3.04 D |
Placebo | 0.32 +/-2.91 D |
Results (p < 0.001) Pupil Size photopic
0.05% | 1.03 +/- 1.02 mm |
0.025% | 0.76 +/- 0.90 mm |
0.01% | 0.49 +/- 0.80 mm |
Placebo | 0.13 +/- 1.07 mm |
LAMP 3 Year Results
How much rebound effect?
LAMP phase 2 -3
Switched the kids on placebo to 0.05% atropine
Found: SE change of 0.18D change in year 2 vs 0.82 in year 1.
AL: 0.15mm year 2 vs 0.43mm in year 1.
Phase 3: Tested washing out … and guess what. Those that washed out progressed faster than kids who stayed in treatment.
Low-Concentration Atropine for Myopia Progression (LAMP) Study
A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia ControlJason C. Yam, FCOphthHK, FRCS(Edin) Yuning Jiang, MMED Shu Min Tang, PhD Clement C. Tham, FCOphthHK, FRCOphthLi Jia Chen, MRCSEd(Ophth), PhD Chi Pui Pang, DPhil Published:July 06, 2018DOI:https://doi.org/10.1016/j.ophtha.2018.05.029
38
SMART Study
CAMP Study
42
Questions
Light Treatment
Light therapy
Questions
Questions?
We think big for little eyes.